GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

PHASE3CompletedINTERVENTIONAL
Enrollment

322

Participants

Timeline

Start Date

November 22, 2010

Primary Completion Date

October 26, 2011

Study Completion Date

December 16, 2016

Conditions
Melanoma
Interventions
DRUG

GSK1120212

MEK inhibitor

DRUG

Chemotherapy

Investigator Choice of DTIC or paclitaxel

Trial Locations (112)

1090

GSK Investigational Site, Vienna

GSK Investigational Site, Jette

1200

GSK Investigational Site, Brussels

2300

GSK Investigational Site, Waratah

2444

GSK Investigational Site, Port Macquarie

2606

GSK Investigational Site, Garran

2610

GSK Investigational Site, Wilrijk

3000

GSK Investigational Site, Leuven

3004

GSK Investigational Site, Melbourne

3084

GSK Investigational Site, Heidelberg

4101

GSK Investigational Site, South Brisbane

4102

GSK Investigational Site, Woolloongabba

4810

GSK Investigational Site, Townsville

5011

GSK Investigational Site, Woodville

5037

GSK Investigational Site, Kurralta Park

5530

GSK Investigational Site, Yvoir

6000

GSK Investigational Site, Charleroi

6002

GSK Investigational Site, Newtown, Wellington

8011

GSK Investigational Site, Christchurch

8036

GSK Investigational Site, Graz

8091

GSK Investigational Site, Zurich

8500

GSK Investigational Site, Kortrijk

9000

GSK Investigational Site, Ghent

9016

GSK Investigational Site, Dunedin

10117

GSK Investigational Site, Berlin

11527

GSK Investigational Site, Athens

20132

GSK Investigational Site, Milan

20133

GSK Investigational Site, Milan

20141

GSK Investigational Site, Milan

21614

GSK Investigational Site, Buxtehude

23538

GSK Investigational Site, Lübeck

29210

GSK Investigational Site, Columbia

30060

GSK Investigational Site, Marietta

30607

GSK Investigational Site, Athens

33916

GSK Investigational Site, Fort Myers

34295

GSK Investigational Site, Montpellier

35042

GSK Investigational Site, Rennes

37044

GSK Investigational Site, Tours

37203

GSK Investigational Site, Nashville

37404

GSK Investigational Site, Chattanooga

38043

GSK Investigational Site, Grenoble

38120

GSK Investigational Site, Memphis

40005

GSK Investigational Site, Sumy

43210

GSK Investigational Site, Columbus

44093

GSK Investigational Site, Nantes

45122

GSK Investigational Site, Essen

46023

GSK Investigational Site, Ternopil

49102

GSK Investigational Site, Dnipro

52242

GSK Investigational Site, Iowa City

56126

GSK Investigational Site, Pisa

61070

GSK Investigational Site, Kharkiv

68167

GSK Investigational Site, Mannheim

69120

GSK Investigational Site, Heidelberg

69495

GSK Investigational Site, Pierre-Bénite

70006

GSK Investigational Site, Metairie

72076

GSK Investigational Site, Tübingen

75475

GSK Investigational Site, Paris

76275

GSK Investigational Site, Zlín

79031

GSK Investigational Site, Lviv

80804

GSK Investigational Site, Munich

88017

GSK Investigational Site, Uzhhorod

92100

GSK Investigational Site, Boulogne-Billancourt

94805

GSK Investigational Site, Villejuif

95023

GSK Investigational Site, Sympheropol

97080

GSK Investigational Site, Würzburg

115478

GSK Investigational Site, Moscow

197758

GSK Investigational Site, Saint Petersburg

454087

GSK Investigational Site, Chelyabinsk

455001

GSK Investigational Site, Magnitogorsk

85724-5024

GSK Investigational Site, Tucson

02114

GSK Investigational Site, Boston

07962-1956

GSK Investigational Site, Morristown

C1121ABE

GSK Investigational Site, Buenos Aires

T2N 4N2

GSK Investigational Site, Calgary

V5Z 4E6

GSK Investigational Site, Vancouver

B3H 2Y9

GSK Investigational Site, Halifax

L8V 5C2

GSK Investigational Site, Hamilton

N6A 4L6

GSK Investigational Site, London

L1G 2B9

GSK Investigational Site, Oshawa

K1H 8L6

GSK Investigational Site, Ottawa

M5G 2M9

GSK Investigational Site, Toronto

H2L 4M1

GSK Investigational Site, Montreal

H2W 1S6

GSK Investigational Site, Montreal

500 05

GSK Investigational Site, Hradec Králové

708 52

GSK Investigational Site, Ostrava

128 08

GSK Investigational Site, Prague

01307

GSK Investigational Site, Dresden

185 47

GSK Investigational Site, Athens

564 29

GSK Investigational Site, Thessaloniki

0310

GSK Investigational Site, Oslo

61-866

GSK Investigational Site, Poznan

02-781

GSK Investigational Site, Warsaw

04-125

GSK Investigational Site, Warsaw

SE-413 45

GSK Investigational Site, Gothenburg

SE-581 85

GSK Investigational Site, Linköping

SE-221 85

GSK Investigational Site, Lund

SE-171 76

GSK Investigational Site, Stockholm

SE-751 85

GSK Investigational Site, Uppsala

03022

GSK Investigational Site, Kyiv

03115

GSK Investigational Site, Kyiv

CB2 2QQ

GSK Investigational Site, Cambridge

HA6 2RN

GSK Investigational Site, Northwood

SM2 5PT

GSK Investigational Site, Sutton

AB25 2ZN

GSK Investigational Site, Aberdeen

B15 2TH

GSK Investigational Site, Birmingham

CM1 7ET

GSK Investigational Site, Chelmsford

LS9 7TF

GSK Investigational Site, Leeds

SW3 6JJ

GSK Investigational Site, London

W1G 6AD

GSK Investigational Site, London

M20 4BX

GSK Investigational Site, Manchester

OX3 7LJ

GSK Investigational Site, Oxford

SO16 6YD

GSK Investigational Site, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01245062 - GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma | Biotech Hunter | Biotech Hunter